Latest News

Research
Wednesday, May 27, 2015
NAAF is pleased to publicize the release of 2015 Research Funding Announcements (RFAs) that outline Research Grant opportunities the support scientists and clinicians at various career stages and in numerous aspects of the field to pursue promising research ideas and innovative projects that will advance the development or discovery of safe, effective, affordable treatments and a cure for alopecia areata. These RFAs were publicized at the Society for Investigative Dermatology (SID) conference in Atlanta, Georgia in early May. This was a fitting venue for announcing RFAs since this meeting...Read more
Research
Friday, April 3, 2015
RXi Pharmaceuticals has entered into a collaboration with Dr. Maria Hordinsky of the University of Minnesota and the National Alopecia Areata Foundation (NAAF) for the study of Samcyprone™ in the treatment of alopecia areata, with the aim to optimize the treatment regimen of diphencyprone is this dermatological disorder, and to better understand the mechanism of action of the drug in this disease. This collaboration could lead to novel targets for development of potent RNAi compounds against this disease based on our sd-rxRNA® platform. Maria K. Hordinsky, M.D. is Professor and Chair of the...Read more
Research
Wednesday, April 1, 2015
On March 22, 2015 a group of seventeen NAAF patient-stakeholders, NAAF staffers Laura Ralph and Maureen Smith, and ten representatives from a biopharmaceutical company convened in New York City, at the request of the biopharma for a focus group to learn more about what patients would want-and not want – in a treatment or cure. The five-hour focus group was filled with personal stories of struggle and triumph, helpful insights about what it means to live with alopecia areata, and important things to consider when developing a treatment such as its safety, efficacy, and durability. All...Read more
Research
Tuesday, March 24, 2015
On March 24, 2015, Genetic Alliance announced the National Alopecia Areata Foundation (NAAF) as one of the fifteen awardees for Phase I of its initiative to create a ‘white label’ of the Platform for Engaging Everyone Responsibly (PEER). PEER enables individuals to share health information with researchers and each other on their own terms to advance an understanding of health and disease, and to accelerate the development of cohorts for clinical trials. The fifteen selected awardees will work with Genetic Alliance to develop and refine the ‘white label’ PEER while engaging their communities...Read more
Research
Tuesday, February 10, 2015
The fifth Alopecia Areata Research Summit, From Targets to Treatments: Bridging Autoimmune Research to Advance Understanding of Alopecia Areata, brought together leading experts with new investigative partners to discuss exciting new discoveries and identify opportunities to further advance alopecia areata research. This meeting, held December 4 to 5 in Bethesda, Maryland, represented a pivotal moment for alopecia areata research and treatment development with early stage clinical trials of drugs targeting auroimmune pathways showing promising hair regrowth for the first time ever. Among the...Read more
Research
Tuesday, February 10, 2015
During the first week of February, President Obama submitted his budget proposal for Fiscal Year 2016 to the newly-installed 114th Congress. It is particularly noteworthy the President’s budget mentions alopecia areata research activities, which indicates that the alopecia areata research portfolio is a priority for the National Institutes of Health (NIH). The President requests $31.31 billion for NIH, a recommended increase of $1 billion over FY 2015, with $533 million of that amount allocated towards NIH's National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS), an...Read more
Research
Wednesday, December 24, 2014
Please note: This article has not been peer-reviewed or vetted by NAAF research advisors. NAAF neither endorses nor discredits the results and claims contained in the article. We pass along this information as it may be of interest to our community. We would appreciate your response if you have any relevant experience.Read more
Research
Monday, June 30, 2014
The National Alopecia Areata Foundation congratulates its advisors, Drs. Raphael Clynes, Angela Christiano and Julian Mackay-Wiggan, and their team at Columbia University Medical Center for their exciting preliminary findings with a drug approved by the FDA for the treatment of myelofibrosis (a type of bone marrow cancer) which has produced near complete hair regrowth in several patients with moderate-to-severe alopecia areata. We applaud the publication of these results in Nature Medicine. This triumph is the result of a long history of Genome Wide Association Studies conducted by Dr...Read more
Research
Tuesday, June 4, 2013
SAN RAFAEL, CA – June 4, 2013 – The National Alopecia Areata Foundation (NAAF) applauds the National Institutes of Health’s (NIH) announcement that NIH scientists and their colleagues have discovered that a gene called BACH2 may play a central role in the development of autoimmune diseases. Since alopecia areata is the most common autoimmune disease – and there are currently no FDAapproved treatments for it -- these findings are of great interest as they point to another promising avenue of research for developing an effective therapy for this disease. In a study, researchers at the National...Read more